Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accumulated Expenses data on file, last reported at $13.9 million in Q1 2026.

• Quarterly Accumulated Expenses fell 30.16% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 30.16% YoY) and the FY2025 annual result came in at $16.5 million, down 30.0% from the prior year.
• Accumulated Expenses eased to $13.9 million in Q1 2026 per CRBU's latest filing, from $16.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $25.4 million in Q3 2024 and bottomed at $100000.0 in Q1 2022.
• The 5-year median for Accumulated Expenses is $18.2 million (2023), against an average of $16.5 million.
• The widest annual swing landed in 2022, when Accumulated Expenses sank 98.5%; it then surged 12444.0% in 2023.
• Tracing CRBU's Accumulated Expenses over 5 years: stood at $16.1 million in 2022, then surged by 31.44% to $21.1 million in 2023, then climbed by 11.76% to $23.6 million in 2024, then retreated by 30.0% to $16.5 million in 2025, then slipped by 16.0% to $13.9 million in 2026.
• Per Business Quant, the three latest CRBU Accumulated Expenses figures stand at $13.9 million (Q1 2026), $16.5 million (Q4 2025), and $19.3 million (Q3 2025).

Peer Comparison